Research article
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
-
* Corresponding author: Carsten Denkert Carsten.Denkert@charite.de
1 Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany
2 GBG Forschungs GmbH, Schleussnerstrasse 42, Neu-Isenburg, 63263, Germany
3 Department of Obstetrics and Gynecology, St. Gertrauden Hospital, Paretzer Str. 12, Berlin, 10713, Germany
4 Department of Obstetrics and Gynecology, Klinikum Südstadt, Südring 81, Rostock, 18059, Germany
5 Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Hospital (HSK), Ludwig-Erhard-Str. 100, Wiesbaden, 65199, Germany
6 Department of Obstetrics and Gynecology, Klinikum Offenbach, Starkenburgring 66, Offenbach am Main, 63069, Germany
7 Institute of Pathology, Berliner Allee 48, Hannover, 30175, Germany
8 Department of Obstetrics and Gynecology, Klinikum der Johann Wolofgang Goethe-Universität, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany
Breast Cancer Research 2009, 11:R69 doi:10.1186/bcr2363
Published: 16 September 2009Additional files
Additional file 1:
A table listing the clinico-pathological characteristics of the study group.
Format: DOC Size: 34KB Download file
This file can be viewed with: Microsoft Word Viewer
